Kalaris Therapeutics, Inc. SEC filings KLRS
Kalaris Therapeutics, Inc. has 699 filings in SEC EDGAR's recent list, going back to Oct 2, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 20, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 10, 2026 | Apr 8, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2026 | Mar 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 18, 2025 | Dec 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 17, 2025 | Dec 17, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2025 | Oct 28, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Aug 13, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Other events
|
Jun 20, 2025 | Jun 19, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 16, 2025 | Apr 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 4, 2025 | Apr 3, 2025 |
| 8-K |
Current report
Acquisition or sale of assets, Results of operations, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Mar 12, 2025 | Mar 12, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jan 15, 2025 | Jan 15, 2025 |
| 8-K |
Current report
Other events
|
Jan 10, 2025 | Jan 9, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jan 10, 2025 | Jan 9, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 8, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Agreement ended
|
Jul 2, 2024 | Jul 1, 2024 |
| 8-K |
Current report
Agreement ended
|
Jun 11, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 3, 2024 | May 31, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 12, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
Jan 4, 2024 | Jan 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 22, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2023 | Nov 2, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 26, 2023 | Jun 21, 2023 |
| 8-K |
Current report
Other events
|
Jun 21, 2023 | Jun 21, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 16, 2023 | May 11, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 23, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 15, 2023 | Feb 15, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 21, 2022 | Nov 21, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 27, 2022 | Jul 26, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 19, 2022 | May 17, 2022 |
| 8-K |
Current report
Results of operations
|
May 5, 2022 | May 5, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 31, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 10, 2022 | Feb 10, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 17, 2021 | Dec 16, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 13, 2021 | Dec 11, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 15, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2021 | Nov 5, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 13, 2021 | Sep 8, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2021 | Aug 6, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 28, 2021 | Jul 22, 2021 |
| 8-K |
Current report
Shareholder vote results
|
May 25, 2021 | May 25, 2021 |
| 8-K |
Current report
Results of operations
|
May 6, 2021 | May 6, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 22, 2021 | Mar 17, 2021 |
| 8-K |
Current report
Results of operations
|
Feb 11, 2021 | Feb 11, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 14, 2021 | Jan 14, 2021 |
| 8-K |
Current report
Other events
|
Dec 17, 2020 | Dec 17, 2020 |
| 8-K |
Current report
Other events
|
Dec 7, 2020 | Dec 7, 2020 |
| 8-K |
Current report
Other events
|
Dec 7, 2020 | Dec 5, 2020 |
| 8-K |
Current report
Material agreement
|
Dec 3, 2020 | Nov 30, 2020 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2020 | Nov 10, 2020 |
| 8-K |
Current report
Other events
|
Sep 17, 2020 | Sep 17, 2020 |
| 8-K |
Current report
Results of operations
|
Sep 2, 2020 | Sep 2, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 3, 2020 | Aug 3, 2020 |
Showing 71 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KLRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1754068
- Former names
- Allovir, Inc. (until Mar 12, 2025); ViraCyte, Inc. (until Oct 2, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.